Therefore, the inclusion criteria were (1) treatment with PD1 inhibitor monotherapy, (2) follow-up time of around 15 weeks, (3) more than 200 patients included and toxicity result available for hypothyroidism. The gene discussed is PDCD1; the disease is hypothyroidism.